gestational trophoblastic tumors

TROPHAMET found that avelumab plus methotrexate achieved very high hCG normalization and durable remission in low-risk gestational trophoblastic tumors, with manageable toxicity and preserved fertility, but randomized trials are still needed.

TROPHAMET found that first-line avelumab plus methotrexate achieved 96.2% hCG normalization in low-risk gestational trophoblastic tumors with manageable toxicity, no relapses at 41 months, and preserved fertility.